Epstein Secrets

ng the Financial Services Scheme, do not a errill Lynch Global Research policies relating to conflicts of interest are de

at current levels. The fundamental bull case for Health rests on the strong pipeline of new products for

s®, | Lynch clients and may not be redistributed, Lynch Global Research reports are distributed horized use or disclosur

ervices 1,720 Tax credit for orphan drug research Health 100 Exclusion & deferral of policyholder income e

®, | Lynch clients and may not be redistributed, Lynch Global Research reports are distributed horized use or disclosure

-12 1% 78 3.0% -13 % 33 -0.4% 6 68% -0./% SXDP (Health) 3.0% -08% 1% 8.7% 0.9% 9 2% 115 2.5% -12 3% 40

up 6.75% on the back of a strong seasonal rally errill Lynch Global Research. Prices reflective of most recently available dat

3% -] 2% 74 3.1% = 2% 3.2 -0.4% 0 54% 0.9% SXDP (Health) 3.1% -0.6% 2% 86% 0.9% -/ 2% 115 24% -14 2% 4]